Doctors and Scientists from UCLA Health Jonsson CompreHensive Cancer Center will share the latest results of research and clinical trials at the annual meeting of 2025 for the annual meeting, annual meeting, annual meeting with radioactive treatment for repetitive cancer cancer. Prostate and the throat of cancers, advanced MR-cancer training.
At this year’s scientific meeting, Dr. Amar Kishan, Executive Vice President of Radiation in UCLA and co-director of the Molecular Cancer Imaging, Nanotechnology and Theranostics program at UCLA Health Jonsson Contremens Cancer Center, will present the findings from the clinical clinical trial (Abstrac 3). For men with repetitive prostate cancer. The results will be highlighted during an oral presentation on Sunday, September 28 at 1:10 pm PDT in the San Francisco Dance Room and is part of Astro News on Monday, September 29 at 11am. PDT.
In addition, Dr. Drew Moghanaki, head of thoracic oncology in the UCLA radiation department, has been named 2025 Astro partner. Recognition is awarded annually to doctors, physicists and scientists in honor of their excellent achievements and constant contributions to society, research on cancer, education, patient care and oncology of radiation oncology, emphasizing the work that promotes critical role.
UCLA studies presented at this year’s Astro meeting offer exciting new ideas for emerging radiation therapies and imaging technologies, showing innovative approaches to treat cancer safer, more accurate and more effective. These presentations emphasize the collaborative efforts of doctors, scientists and trainees and reflect the long -term leadership and UCLA’s commitment to promoting cancer care. “
Dr. Michael Steinberg, Professor and President of Radiation at the David Geffen Medical School in UCLA and Clinical Affairs Director at UCLA Health Jonsson Comprehensive Cancer Center
The main points of remarkable presentations from the UCLA School in Astro include:
Summary 148: Four -year Results from the SCIMITAR test Test Stereotactic Body Radiation Therapy After Prostate Surgery
Dr. Jesus Juarez Casillas, a resident of the Radiation Department in UCLA, will present findings from the Phase II Scimitar Phase Clinical Test, which evaluated Stereotactic Body Radiotherapy (SBRT) in men at risk of prostate cancer. After four years, 62% of patients had no signs of cancer return, local relapses were rare and the results compared to conventional radiation approaches. The research, led by Kishan, will be presented on Sunday, September 28 at 5:05 pm PDT in room 24.
Summary 253: 5DCT provides more accurate illustration of lung tumors for patients with irregular breathing
Dr. Daniel Low, a professor and vice president of Medical Physics and Innovation Research in the Radiation Department in UCLA, will report the findings from the first large 5DCT study, a new CT imaging technique aimed at improving scanning for patients with lung -breathable pulmonary tumors. Unlike conventional 4Dct, which can produce unreliable images, 5Dct represents the breath of motion in three dimensions as well as the rhythm and depth of any breath, producing clearer images without artificial. In a study of 108 patients, 5Dct allowed clinical doctors to more accurately determine the size and movement of the tumor, supporting the best radiation design. The workflow was reliable for almost all patients, even those with very variable breathing patterns, and is now used for the development of automated imaging processes such as CT CT CT CT. The results will be presented on Monday, September 29 at 3:10 pm PDT in Room 155/157.
Summary 1005: Comparing the acute side effects of the SBRT prostate with MRI guided with and without adaptive dose painting
Dr. Travis Courtney, head of the UCLA radiation section, presents a research that compares two forms of MR-MRI guided targeted radiotherapy for prostate cancer. The study examined the standard high -dose body stereotactic radiotherapy (MRGSBRT) in relation to an adaptive “dose painted” approach that enhances radiation in dominant tumor areas, reducing the dose in the surrounding tissue. The results showed that patients receiving adaptive dose therapy had higher acute side effects such as doctors, particular symptoms of urine and intestinal. However, the quality of life reported by the patient were similar between the two groups. The findings indicate that increasing the dose in specific tumor areas may not reduce the side effects and underline the need for further study as the test continues to record patients. The project, led by Kishan, will be presented on Monday, September 29 at 8:30 am. PDT in Room 307/308.
Summary 1003: Analysis of sexual function after MRI-Guided SBRT prostate in Mirage Test
Dr. Jonathan Massachi, a Radiation resident in UCLA, will discuss the findings from the Mirage test that examined sexual function in men receiving SBRT for prostate cancer, comparing the SBRT standard with CT with SBRT MRI. Despite the use of MRI guidance to reduce radiation exposure to basic nerves and blood vessels, almost one -third of men in both groups showed a significant reduction in sexual function two years after treatment. Factors such as hormone therapy, pelvic radiation and the sexual function of the base line were associated with these changes. The findings indicate that while the SBRT MRI guided can reduce some exposure to radiation, additional strategies such as boat cutting techniques may be needed to better maintain sexual function in men undergoing prostate cancer treatment. The study, led by Kishan, will be presented on Monday, September 29 at 8:20 am. In Room 307/308.
Summary 2785: Postoperative stereotactic body radiation therapy shows promise for head and neck cancer
Dr. Miriam Lane, a Radiation resident in UCLA, will present findings from a study evaluating SBRT postoperative for patients with newly -known or recurrent head and neck cancer. The study found that the SBRT was well tolerated, without severe acute side effects and only two delayed serious toxicities, although about half patients had cancer relapse within two years. The results were similar to the newly diagnosed and repeated cases. The study, led by Dr. Ricky Savjani, Assistant Professor of Oncology Radiation at David Geffen School of Medicine in UCLA, suggests that Postoperative SBRT is a feasible, less therapeutic option, and further research is needed to optimize patients’ choice and improve results. The survey will be presented on Monday, September 29 at 10:45 am In Hall F.
Summary 139: Study identifies genetic drivers of prostate cancer
Dr. Beth Neilsen, a former Radiation resident in UCLA, will discuss the findings from a study that analyzed tumors from patients with prostate cancer who returned after radiotherapy. Research, led by Kishan, revealed that these repetitive tumors have a higher frequency of mutations in genes associated with aggressive disease and defective DNA repair, including BRCA1, BRCA2, RAD51B and Polq. Compared to cancers who have not been treated, they have also shown more aggressive molecular subtypes, higher genomic risk ratings, and reduced androgen receptor activity. These ideas shed light on why some prostate cancers resist radiation and can help guide future treatment approaches. The findings will be presented on Sunday, September 28 at 3:30 pm PDT in Room 155/157.
EDU session 29: Strengthening patients through innovation: Enhancing cancer training with digital tools
Dr Trudy Wu, Assistant Professor of Oncology Radiation in UCLA, will mitigate a team that will explore how digital tools convert cancer education. Participants Dr. David grew up, Dr. Hyunsoo No and patient lawyer Jill Feldman will share strategies for making complex cancer information, such as treatment options, side effects and prognosis, more understandable and accessible. The meeting highlights animations, educational videos and resources focusing on the patient aiming to reduce fear, improve understanding and support better decision -making for patients who navigate cancer. The session is on Monday, September 29 at 5 pm PDT in room 152.
